Teva Pharmaceutical Industries Ltd. ADR-3.78% $21.4B ...
Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback